Patient AF is a 66-year-old female who is enrolled in Medicare Part D for her prescription drug plan. Her MRIs and MS symptoms have remained stable since initiation of ofatumumab in 2022. However, since switching to Medicare Part D, she is unable to afford ofatumumab due to having an out-of-pocket cost of $500 per month. She makes slightly above the income cutoff for patient assistance enrollment. Starting in 2025, what information is correct regarding the Inflation Reduction Act that would be helpful for patient AF’s DMT affordability? A. Annual out-of-pocket costs will be capped at $2,000 for people with Medicare Part D B. Annual out-of-pocket costs will be capped at $8,000 for people with Medicare Part D C. Patients enrolled in Medicare part D do not have the option to pay out-of-pocket prescription drug costs in the form of monthly installment payments instead of all at once at the pharmacy D. The changes to the out-of-pocket costs for Medicare part D recipients does not apply to patient AF because ofatumumab is a self-injection
[Verified Answer]: Patient AF is a 66-year-old female who is…
Need help with your Clinical Case Studies case study or NCLEX preparation? Connect with a verified Nursing expert now.